Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 16Leukemia, Myelomonocytic, Chronic 7Recurrence 6Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Leukemia, Myeloid 2Carcinoma, Non-Small-Cell Lung 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Polycythemia Vera 1Pathologic Complete Response 1Myeloproliferative Disorders 1Melanoma 1Malignant Solid Tumor 1Hematologic Diseases 1Carcinoma, Renal Cell 1Bone Marrow Diseases 1Blast Crisis 1Advanced Breast Cancer 1

Interventions

nilotinib 50Imatinib Mesylate 48Dasatinib 25bosutinib 18asciminib 17ponatinib 10Homoharringtonine 5Cytarabine 4olverembatinib 3Interferon-alpha 3Decitabine 3tozasertib 2peginterferon alfa-2a 2flumatinib 2fludarabine phosphate 2ON 01910 2Mycophenolic Acid 2Melphalan 2Interferon alpha-2 2Filgrastim 2Cyclophosphamide 2Bone Marrow Transplantation 2BID protein, human 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1troxacitabine 1triciribine 1terameprocol 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Decitabine × Clear all
NCT00042003 2024-08-02

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Astex Pharmaceuticals, Inc.

Phase 2 Completed
40 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00042016 2009-10-14

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Astex Pharmaceuticals, Inc.

Phase 2 Completed
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00041990 2007-12-17

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Astex Pharmaceuticals, Inc.

Phase 2 Completed
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡